Gene
FLCN
FLCN is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (2), Trial mentions (19), Target-disease associations (267), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FLCN. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 4 of 11,460 | 0.03% |
| 2022 | 1 of 8,285 | 0.01% | 6 of 13,598 | 0.04% |
| 2021 | 1 of 8,692 | 0.01% | 3 of 15,045 | 0.02% |
| 2020 | 1 of 7,640 | 0.01% | 2 of 14,459 | 0.01% |
| 2019 | 2 of 7,300 | 0.03% | 1 of 12,159 | 0.01% |
| 2018 | 2 of 6,927 | 0.03% | 1 of 11,854 | 0.01% |
| 2017 | 0 of 6,558 | 0.00% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FLCN oncogenic mutation | EVEROLIMUS | response-associated | renal carcinoma | Cancer Genome Interpreter |
| FLCN deletion | EVEROLIMUS | response-associated | thyroid carcinoma | Cancer Genome Interpreter |
Trial mentions (19)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05794100 | Trial eligibility (AACT) |
| NCT05820087 | Trial eligibility (AACT) |
| NCT06076538 | Trial eligibility (AACT) |
| NCT03390413 | Trial eligibility (AACT) |
| NCT06907095 | Trial eligibility (AACT) |
Showing 5 of 19 trial mentions.
Target-disease associations (267)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Autosomal dominant familial hematuria - retinal arteriolar tortuosity - contractures | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| B-cell acute lymphoblastic leukemia | cancer or benign tumor | Cancer Gene Census |
| Birt-Hogg-Dube syndrome | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 267 associations.
Vendor sourcing (82)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Frameshift: predicted to result in a loss or disruption of normal p... | View ClinVar record SCV006584636.1 |
| A. Manzoni Hospital | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Male and female patients, aged ≥ 18, stabilized on BHD for at least 6 months. 2. Clinical stability during the last 3 months. 3. Serum Ferritin \> 200 ... | View trial NCT00687258 |
| A. Manzoni Hospital | Trial sponsor | Mentioned in trial textTrial free-text mention | BHD | View trial NCT00687258 |
| AIDP, Inc. (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Males and females 18 to 60 years of age, inclusive at baseline * Female participant is not of child bearing potential, defined as females who have had a... | View trial NCT03462199 |
| AIDP, Inc. (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | BHD | View trial NCT03462199 |
Showing 5 of 82 sourcing records.
Trial-cited literature (41)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis. | Current problems in cardiology | 2023 | 18 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies. | Scientific reports | 2023 | 3 |
| Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients. | Cancer medicine | 2023 | 1 |
| Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. | Signal transduction and targeted therapy | 2022 | 2,107 |
Showing 5 of 41 papers.
Protein variant mentions (87)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A225T | 1 | 2015 | PMID 25741868 |
| p.A489T | 1 | 2015 | PMID 25741868 |
| p.A60V | 1 | 2015 | PMID 25741868 |
| p.A64T | 1 | 2015 | PMID 25741868 |
| p.D545E | 1 | 2015 | PMID 25741868 |
Showing 5 of 87 variants.
Literature-extracted relations (20)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Birt-Hogg-Dube Syndrome | Disease | associate |
Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice. | 2022 |
| Cysts | Disease | associate |
Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice. | 2022 |
| Pneumothorax | Disease | associate |
Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice. | 2022 |
| Birt-Hogg-Dube Syndrome | Disease | associate |
Birt-Hogg-Dubé syndrome in a patient presenting with familial spontaneous pneumothorax. | 2014 |
| Birt-Hogg-Dube Syndrome | Disease | associate |
Birt-Hogg-Dube syndrome: clinicopathological features of the lung. | 2013 |
Showing 5 of 20 relation assertions.
Organizations publishing (55)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Central South University | Academic | 3 | 2022 to 2023 |
| Beth Israel Deaconess Medical Center | Hospital | 2 | 2014 to 2023 |
| Government of the United States of America | Government | 2 | 2013 to 2020 |
| Harris Health System | Hospital | 2 | 2016 |
| Harvard Medical School | Academic | 2 | 2014 to 2023 |
Showing 5 of 55 organizations.
Where FLCN appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
216 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.